2 terminated. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
| Phase 2 | 1 | Terminated 1 |
Follow Ventricular Dysfunction, Right: new trials by email Literature Review of Ventricular Dysfunction, Right trials Research Report on Ventricular Dysfunction, Right
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE Conventional catheter-directed thrombolysis (CDT) with recombinant tissue plasminogen activator (rtPA), Enoxaparin - Pulmonary Embolism, Pulmonary Thromboembolisms | Phase 3 | Terminated | Rajaie Cardiovascular Medical and Research Center | 94 | 2018-12-22 | 2021-12-29 |
| Diclofenac for Submassive PE Diclofenac, Placebo - Pulmonary Embolism | Phase 2 / Phase 3 | Terminated | Ministry of Health, Spain | 34 | 2012-05-01 | 2017-09-06 |
Pulmonary Embolism (2) · Inflammation (1)
Cardiovascular Diseases (2) · Embolism (2) · Embolism and Thrombosis (2) · Heart Diseases (2) · Lung Diseases (2) · Respiratory Tract Diseases (2) · Vascular Diseases (2) · Ventricular Dysfunction (2) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Diclofenac (1) · Enoxaparin (1) · Heparin, Low-Molecular-Weight (1) · carbohydrate-deficient transferrin (1)
Ministry of Health, Spain (1) · Rajaie Cardiovascular Medical and Research Center (1)
Iran (1) · Spain (1)
David Jimenez, MD, PhD (1) · Parham Sadeghipour, M.D (1)